Crohn's Disease Clinical Trials in Fort Worth, Texas

5 studies are recruiting for crohn's disease in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study i…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance, Fort Worth, Texas

   Locations

   201 in total

   Run by

   Takeda

   See if you can join NCT06233461 on ClinicalTrials.gov

2. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Gi Alliance - Texas Digestive Disease Consultants - Fort Worth /ID# 283977, Fort Worth, Texas

   Locations

   66 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

3. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

   The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

   Stage

   Phase 3

   Ages

   2 to 19

   Site

   Cook Children's Medical Center, Fort Worth, Texas

   Locations

   69 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT04844606 on ClinicalTrials.gov

4. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

   Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Cook Children's Medical Center, Fort Worth, Texas

   Locations

   81 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05509777 on ClinicalTrials.gov

5. A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Cook Childrens Medical Center, Fort Worth, Texas

   Locations

   85 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05923073 on ClinicalTrials.gov